tiprankstipranks
Ping An Healthcare and Technology Company Limited (HK:1833)
:1833
Want to see HK:1833 full AI Analyst Report?

Ping An Healthcare and Technology Company (1833) AI Stock Analysis

17 Followers

Top Page

HK:1833

Ping An Healthcare and Technology Company

(1833)

Select Model
Select Model
Select Model
Neutral 57 (OpenAI - Gpt-5.6Sol)
Rating:57Neutral
Price Target:
HK$7.00
▲(5.42% Upside)
Action:Reiterated
Date:08/21/26
The overall score is supported primarily by improving financial performance (return to profitability, stronger 2025 results, and very low leverage with improving cash flow), but is held back materially by weak technicals (price below all key moving averages and negative MACD). Valuation is only moderate given a 25.65 P/E and no dividend yield provided.
Positive Factors
Profitability Turnaround
The shift from multi-year losses to sustained profitability improves the company’s ability to fund operations internally and demonstrates that its healthcare platform can operate with stronger economic discipline.
Negative Factors
Volatile Revenue Trend
Recent recovery has not yet established a consistently compounding top line. Prior contractions indicate that demand, monetization, or competitive conditions can materially affect the platform’s revenue trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The shift from multi-year losses to sustained profitability improves the company’s ability to fund operations internally and demonstrates that its healthcare platform can operate with stronger economic discipline.
Read all positive factors

Ping An Healthcare and Technology Company (1833) vs. iShares MSCI Hong Kong ETF (EWH)

Ping An Healthcare and Technology Company Business Overview & Revenue Model

Company Description
Ping An Healthcare and Technology Company Limited (PAHT), through its subsidiaries, operates a comprehensive online platform that delivers healthcare services across the People's Republic of China. Its core offerings encompass virtual medical cons...
How the Company Makes Money
The company generates revenue primarily by monetizing healthcare services and platform capabilities. Key revenue streams include: (1) Healthcare service revenue from online medical services and health-related offerings delivered through its platfo...

Ping An Healthcare and Technology Company Financial Statement Overview

Summary
Financials show a credible turnaround: profitability improved from multi-year losses to positive net income in 2024 and stronger profits in 2025, with positive EBIT/stronger EBITDA and steadier gross margin (~31–32% in 2023–2025). Balance sheet risk is low due to extremely low leverage, and cash flow turned positive in 2024 and strengthened in 2025. Offsets include historically volatile revenue (sharp contraction in 2022–2023 before rebounding) and uneven cash conversion across years.
Income Statement
63
Positive
Balance Sheet
82
Very Positive
Cash Flow
60
Neutral
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.42B5.47B4.81B4.67B6.21B7.33B
Gross Profit1.88B1.77B1.52B1.51B1.67B1.71B
EBITDA354.60M238.67M193.43M-164.23M-1.05B-1.76B
Net Income461.65M379.51M81.43M-322.59M-636.06M-1.54B
Balance Sheet
Total Assets13.08B13.24B16.78B16.52B17.14B17.88B
Cash, Cash Equivalents and Short-Term Investments7.20B6.97B11.52B11.35B10.14B10.14B
Total Debt29.05M39.81M45.00M93.61M176.49M201.29M
Total Liabilities3.01B3.33B13.20B3.25B3.68B3.79B
Stockholders Equity10.08B9.92B3.59B13.28B13.46B14.08B
Cash Flow
Free Cash Flow344.67M391.83M65.08M-325.82M-845.05M-1.49B
Operating Cash Flow387.36M430.72M99.33M-282.86M-810.62M-1.40B
Investing Cash Flow1.23B3.04B114.65M-1.49B1.71B-3.10B
Financing Cash Flow-113.55M-3.84B-38.44M-67.36M-317.88M-319.91M

Ping An Healthcare and Technology Company Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.64
Price Trends
50DMA
7.28
Negative
100DMA
8.51
Negative
200DMA
11.24
Negative
Market Momentum
MACD
-0.31
Positive
RSI
40.04
Neutral
STOCH
31.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1833, the sentiment is Negative. The current price of 6.64 is below the 20-day moving average (MA) of 6.86, below the 50-day MA of 7.28, and below the 200-day MA of 11.24, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.04 is Neutral, neither overbought nor oversold. The STOCH value of 31.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1833.

Ping An Healthcare and Technology Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
HK$1.63B8.9243.78%11.45%-14.68%-13.60%
71
Outperform
HK$5.17B13.037.00%4.49%6.47%8.10%
57
Neutral
HK$14.25B25.154.62%160.60%7.92%152.75%
56
Neutral
HK$1.04B-13.91-3.87%8.73%80.38%
52
Neutral
HK$4.04B49.561.88%1.05%16.87%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1833
Ping An Healthcare and Technology Company
6.47
-15.42
-70.45%
HK:9886
Dingdang Health Technology Group Ltd.
0.80
-0.10
-11.11%
HK:1830
Perfect Medical Health Management Limited
1.27
-0.12
-8.90%
HK:2158
Yidu Tech, Inc.
3.81
-2.27
-37.38%
HK:2192
Medlive Technology Co., Ltd.
7.01
-6.49
-48.08%
HK:2506
Xunfei Healthcare Technology Co., Ltd.
70.90
-34.70
-32.86%

Ping An Healthcare and Technology Company Corporate Events

Ping An Healthcare Sets Out Board and Committee Structure
Aug 18, 2026
Ping An Healthcare and Technology Company Limited has announced the current composition of its board of directors and clarified the roles of executive, non-executive, and independent non-executive members. The board is led by chairman Yougang Zhu ...
Ping An Healthcare Overhauls Board with New Leadership from Ping An Group
Aug 18, 2026
Ping An Healthcare and Technology Company Limited announced extensive board changes, with five directors, including several non-executive and an independent non-executive director, resigning effective 19 August 2026 due to personal work arrangemen...
Ping An Healthcare and Technology Publishes Unaudited 2026 Interim Results
Aug 18, 2026
Ping An Healthcare and Technology Company Limited, a Hong Kong-listed provider of technology-enabled healthcare services, operates within the broader Ping An Group framework and targets the mainland Chinese market. The company is incorporated in t...
Ping An Healthcare Schedules Board Meeting to Review Interim Results and Dividend
Jul 13, 2026
Ping An Healthcare and Technology Company has scheduled a board meeting for 18 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also consider the potential declaration and payment of an in...
Ping An Healthcare Unit Signs Connected Office Lease With Ping An Bank Arm
Jun 30, 2026
Ping An Healthcare and Technology Company Limited has entered into a connected transaction through its wholly owned subsidiary Kang Jian Information Technology (Shenzhen) Co., Ltd., which signed a three-year lease with Ping An Bank’s Credit ...
Ping An Healthcare and Technology reshapes finance and governance leadership
Jun 16, 2026
Ping An Healthcare and Technology Company has announced the resignation of executive director and chief financial officer Luoqi Zang, who also stepped down as secretary to the board, company secretary and authorized representative, citing personal...
Ping An Healthcare Outlines Board and Committee Structure
Jun 16, 2026
Ping An Healthcare and Technology Company Limited has announced the current composition of its board of directors, which includes a chief executive officer, a non-executive chairman, several non-executive directors, and three independent non-execu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2026